di- n- butylaminocarbamyl- leucyl- tryptophyl- 4- chlorophenylalanine

structure in first source

Also Known As:

GF 063; GF-063; GF063 cpd; di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Pulmonary Hypertension 09/01/2010 - "Aiming at developing new endothelin-A receptor (ETA) antagonist for treatment of pulmonary hypertension, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe, named GF063, was synthesized at base of selective ETA receptor antagonist BQ485 and selected for the further pharmacological characterization. "
2.	Hypoxia (Hypoxemia) 09/01/2010 - "Inhibition of endothelin-1 and hypoxia-induced pulmonary pressor responses in the rat by a novel selective endothelin-A receptor antagonist, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe."